论文部分内容阅读
目的:比较姜黄素羟丙基-β-环糊精磷脂复合物、姜黄素羟丙基-β-环糊精包合物、姜黄素磷脂复合物、姜黄素原料药在大鼠体内的药动学特征,探讨姜黄素羟丙基-β-环糊精磷脂复合物作为药物载体的优势。方法:SD大鼠口服灌胃给予姜黄素药物制剂及游离药物后,不同时间点于大鼠眼底静脉丛取血。采用HPLC法测定血浆中姜黄素的浓度。结果:姜黄素羟丙基-β-环糊精磷脂复合物的AUC0-∞为(1 126.20±323.24)μg/(L·h),较原料药姜黄素(191.08±43.27)μg/(L·h)、姜黄素磷脂复合物(754.93±55.33)μg/(L·h)、姜黄素羟丙基-β-环糊精包合物(961.21±253.65)μg/(L·h)均有所提高,分别为其5.89、1.49、1.17倍。结论:姜黄素羟丙基-β-环糊精磷脂复合物较单一的磷脂复合物或羟丙基-β-环糊精包合物更能促进药物的吸收,有利于提高药物的生物利用度。
OBJECTIVE: To compare pharmacokinetics of curcumin hydroxypropyl-β-cyclodextrin phospholipid complex, curcumin hydroxypropyl-β-cyclodextrin inclusion complex, curcumin phospholipid complex and curcumin raw material in rats Learn characteristics of curcumin hydroxypropyl-β-cyclodextrin phospholipid complex as a drug carrier advantage. Methods: SD rats were orally administered with curcumin and free drug, and blood was collected from the venous plexus of rats at different time points. The concentration of curcumin in plasma was determined by HPLC. Results: The AUC0-∞ of curcumin hydroxypropyl-β-cyclodextrin phospholipid complex was (1 126.20 ± 323.24) μg / (L · h), higher than curcumin of curcumin (191.08 ± 43.27) μg / h), curcumin phospholipid complex (754.93 ± 55.33) μg / (L · h), curcumin hydroxypropyl-β-cyclodextrin inclusion complex (961.21 ± 253.65) μg / (L · h) Increase, respectively, 5.89,1.49,1.17 times. CONCLUSION: The curcumin hydroxypropyl-β-cyclodextrin phospholipid complex can promote the absorption of the drug more than single phospholipid complex or hydroxypropyl-β-cyclodextrin inclusion complex, which is beneficial to improve the bioavailability of the drug .